• Le Vosaroxin pour traiter la leucémie myéloïde aiguë

Posté : **mar. mai 08, 2012 4:36 pm**

Le Vosaroxin dans le traitement de la leucémie myéloïde aiguë.
''If data for Vosaroxin confirms the Phase III trials, the standard of care for patients who relapse from this form of Leukemia (AML) will change drastically. With no competing drugs, the company estimates potential Vosaroxin sales, if approved, could range from $400-$600 million annually.''
Extrait de Sunesis Pharma: Promising Leukemia Drug With Potential

Autres liens:
Valor Trial
Vosaroxin - Treatment for Myeloid Leukaemia, United States of America
..........

Posté : **mar. mai 08, 2012 10:23 pm**

Merci Gilles pour cette info.
Voici un petit extrait :
Vosaroxin - Treatment for Myeloid Leukaemia, United States of America
Drug Vosaroxin Company Sunesis Pharmaceuticals Therapy Class Topoisomerase II inhibitor Product Description Anticancer Quinolone Derivative Current Indications Acute Myeloid Leukaemia (AML) and platinum-resistance ovarian cancer Market Sector Oncology Development Status Phase III
Vosaroxin is a first-in-class anticancer quinolone derivative (AQD) under development by Sunesis Pharmaceuticals for the treatment of acute myeloid leukaemia (AML). It is the leading drug candidate of the company and is currently undergoing Phase III clinical trials.
On 23 February 2011, the drug was granted fast track designation by the US FDA for the treatment of relapsed or refractory AML in combination with cytarabine. It received orphan drug designation in 2009.
In order to accelerate timelines and extend indications for Vosaroxin, Sunesis is seeking a partner to co-develop the drug. The drug is also being evaluated in clinical trials for platinum-resistance ovarian cancer.
In August 2011, the US Patent and Trademark Office issued a patent covering Vosaroxin. Patent applications are pending for approval in Europe, Japan, Australia and Canada
Qui achètera la licence ?
En tout cas un espoir pour les leucémies myéloblastiques post SMP.

Le Vosaroxin pour traiter la leucémie myéloïde aiguë

Le Vosaroxin pour traiter la leucémie myéloïde aiguë

Re: Le Vosaroxin pour traiter la leucémie myéloïde aiguë